Related references
Note: Only part of the references are listed.A novel TanCAR targeting IL13Rα2 and EphA2 for enhanced glioblastoma therapy
Niaz Muhammad et al.
MOLECULAR THERAPY-ONCOLYTICS (2022)
Remodeling metabolic fitness: Strategies for improving the efficacy of chimeric antigen receptor T cell therapy
Luyan Shen et al.
CANCER LETTERS (2022)
Engineering Next-Generation CAR-T Cells: Overcoming Tumor Hypoxia and Metabolism
Torahito A. Gao et al.
ANNUAL REVIEW OF CHEMICAL AND BIOMOLECULAR ENGINEERING (2022)
Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models
Shunsuke Goto et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Chemokines and the immune response to cancer
Aleksandra J. Ozga et al.
IMMUNITY (2021)
Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors
Bruno L. Cadilha et al.
SCIENCE ADVANCES (2021)
T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours
Stefanie Lesch et al.
NATURE BIOMEDICAL ENGINEERING (2021)
CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma
Guangna Liu et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2020)
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Sarwish Rafiq et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
The Role of Antigen Spreading in the Efficacy of Immunotherapies
Peter Brossart
CLINICAL CANCER RESEARCH (2020)
Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers
Sareetha Kailayangiri et al.
CANCERS (2020)
Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity
Junyun Lai et al.
NATURE IMMUNOLOGY (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Engineering CAR-T Cells for Next-Generation Cancer Therapy
Mihe Hong et al.
CANCER CELL (2020)
Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment
Jort J. van der Schans et al.
FRONTIERS IN ONCOLOGY (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies
Lynsey M. Whilding et al.
CANCERS (2019)
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors
Denarda Dangaj et al.
CANCER CELL (2019)
The Tumor Microenvironment Innately Modulates Cancer Progression
Dominique C. Hinshaw et al.
CANCER RESEARCH (2019)
Target selection for CAR-T therapy
Jianshu Wei et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells
Masao Nakajima et al.
CANCER SCIENCE (2019)
CXCR1-or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors
Linchun Jin et al.
NATURE COMMUNICATIONS (2019)
Heparanase: A Challenging Cancer Drug Target
Deirdre R. Coombe et al.
FRONTIERS IN ONCOLOGY (2019)
Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment
Daisuke Umezu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment
Marina Martinez et al.
FRONTIERS IN IMMUNOLOGY (2019)
Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
Jang Hwan Cho et al.
CELL (2018)
IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
Keishi Adachi et al.
NATURE BIOTECHNOLOGY (2018)
Rewiring T-cell responses to soluble factors with chimeric antigen receptors
Zenan L. Chang et al.
NATURE CHEMICAL BIOLOGY (2018)
Understanding the tumor immune microenvironment (TIME) for effective therapy
Mikhail Binnewies et al.
NATURE MEDICINE (2018)
Targeting the tumour stroma to improve cancer therapy
Kenneth C. Valkenburg et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Chimeric Antigen Receptor Therapy
Carl H. June et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Sarwish Rafiq et al.
NATURE BIOTECHNOLOGY (2018)
Tumor Antigen Escape from CAR T-cell Therapy
Robbie G. Majzner et al.
CANCER DISCOVERY (2018)
Emerging Cellular Therapies for Cancer
Sonia Guedan et al.
Annual Review of Immunology (2018)
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Frederick L. Locke et al.
MOLECULAR THERAPY (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Donald M. O'Rourke et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
Levi J. Rupp et al.
SCIENTIFIC REPORTS (2017)
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
Nicholas McGranahan et al.
CELL (2017)
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
Aurore Morello et al.
CANCER DISCOVERY (2016)
Extracellular matrix structure
Achilleas D. Theocharis et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
Coinhibitory Pathways in Immunotherapy for Cancer
Susanne H. Baumeister et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 34 (2016)
A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
Xiaojun Liu et al.
CANCER RESEARCH (2016)
Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition
Helene Salmon et al.
IMMUNITY (2016)
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Leonid Cherkassky et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape (Publication with Expression of Concern. See vol. 129, pg. 3464, 2019)
Meenakshi Hegde et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Versatile strategy for controlling the specificity and activity of engineered T cells
Jennifer S. Y. Ma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies
David T. Rodgers et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model
Eloah Rabello Suarez et al.
ONCOTARGET (2016)
The paradoxical role of IL-10 in immunity and cancer
Mark H. Mannino et al.
CANCER LETTERS (2015)
Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy
Keishi Adachi et al.
CANCER SCIENCE (2015)
Effects of extracellular pH and hypoxia on the function and development of antigen-specific cytotoxic T lymphocytes
Yohko Nakagawa et al.
IMMUNOLOGY LETTERS (2015)
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
Lieping Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
Ignazio Caruana et al.
NATURE MEDICINE (2015)
Selective and efficient generation of functional Batf3-dependent CD103+ dendritic cells from mouse bone marrow
Christian Thomas Mayer et al.
BLOOD (2014)
Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression?
Theresa L. Whiteside
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma
Meenakshi Hegde et al.
MOLECULAR THERAPY (2013)
Microenvironmental regulation of tumor progression and metastasis
Daniela F. Quail et al.
NATURE MEDICINE (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies
Koji Tamada et al.
CLINICAL CANCER RESEARCH (2012)
Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors
Helene Salmon et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
Edmund K. Moon et al.
CLINICAL CANCER RESEARCH (2011)
Effector T-Cell Infiltration Positively Impacts Survival of Glioblastoma Patients and Is Impaired by Tumor-Derived TGF-β
Jennifer Lohr et al.
CLINICAL CANCER RESEARCH (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b
John A. Craddock et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression
Ethan M. Shevach
IMMUNITY (2009)
Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells
Alexander Link et al.
NATURE IMMUNOLOGY (2007)
Tumor-driven evolution of immunosuppressive networks during malignant progression
Ryungsa Kim et al.
CANCER RESEARCH (2006)
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia
C Imai et al.
LEUKEMIA (2004)
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
ME Dudley et al.
SCIENCE (2002)
Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis
SA Luther et al.
JOURNAL OF IMMUNOLOGY (2002)
Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells
JT Tan et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR zeta/CD28 receptor
J Maher et al.
NATURE BIOTECHNOLOGY (2002)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)
Share Paper
